Literature DB >> 12925328

A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker.

Martin W McIntosh1, Nicole Urban.   

Abstract

A revolution in molecular technology is leading to the discovery of many biomarkers of disease. Monitoring these biomarkers in a population may lead to earlier disease detection, and may prevent death from diseases like cancer that are more curable if found early. For markers whose concentration is associated with disease progression the earliest detection is achieved by monitoring the marker with an algorithm able to detect very small changes. One strategy is to monitor the biomarkers using a longitudinal algorithm that incorporates a subject's screening history into screening decisions. Longitudinal algorithms that have been proposed thus far rely on modeling the behavior of a biomarker from the moment of disease onset until its clinical presentation. Because the data needed to observe the early pre-clinical behavior of the biomarker may take years to accumulate, those algorithms are not appropriate for timely development using new biomarker discoveries. This manuscript presents a computationally simple longitudinal screening algorithm that can be implemented with data that is obtainable in a short period of time. For biomarkers meeting only a few modest assumptions our algorithm uniformly improves the sensitivity compared with simpler screening algorithms but maintains the same specificity. It is unclear what performance advantage more complex methods may have compared with our method, especially when there is doubt about the correct model for describing the behavior of the biomarker early in the disease process. Our method was specifically developed for use in screening for cancer with a new biomarker, but it is appropriate whenever the pre-clinical behavior of the disease and/or biomarker is uncertain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925328     DOI: 10.1093/biostatistics/4.1.27

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  30 in total

1.  Designing early detection programs for ovarian cancer.

Authors:  N Urban
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

2.  Screening for prostate cancer using multivariate mixed-effects models.

Authors:  Christopher H Morrell; Larry J Brant; Shan Sheng; E Jeffrey Metter
Journal:  J Appl Stat       Date:  2012-06-01       Impact factor: 1.404

3.  Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Authors:  Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

4.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

5.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

6.  Patient-reported outcomes and the mandate of measurement.

Authors:  Gary Donaldson
Journal:  Qual Life Res       Date:  2008-10-25       Impact factor: 4.147

7.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

8.  Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Authors:  Charles W Drescher; Chirag Shah; Jason Thorpe; Kathy O'Briant; Garnet L Anderson; Christine D Berg; Nicole Urban; Martin W McIntosh
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

9.  Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Authors:  Kimberly A Lowe; Chirag Shah; Erin Wallace; Garnet Anderson; Pamela Paley; Martin McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay Bergan; Jason Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

10.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.